Drugs / AIDSVAX B/E
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03391375 | Mar 2017 → Jan 2018 | HIV infectious disease | EuroVacc Foundation | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AIDSVAX B/E | “AIDSVAX®B/E is a subtype B (MN) and subtype E (A244) HIV gp120 glycoprotein adsorbed onto aluminium hydroxide gel adjuvant” NCT03391375 ↗1“DNA-HIV-PT123 & AIDSVAX B/E” NCT03391375 ↗ |